SDIX, a Glasgow, Del. provider of biotechnology-based products and services reported a loss for the quarter and a partnership with a drug company. Revenue for the first quarter of 2012 was $5.6 million, down from $6.6 million for the same period in 2011.
Net loss for the first quarter of 2012 was $1.2 million, compared to a net loss of $658,000 for the same period in 2011. Net loss for the first quarter of 2011 included income from discontinued operations of $388,000.
The company also announced that it has established a collaborative relationship with a top 10 pharmaceutical company. Click on the link below for the full report.
